ALK and non-small cell lung carcinoma: The first phase III clinical trial, IMpower130, which recruited 723 patients with non-squamous NSCLC tumors with EGFR/ALK wild-type status, was set to evaluate the effectiveness and safety of the combinatorial treatment of atezolizumab than treatment with chemotherapy (carboplatin/nab-paclitaxel)-alone (Cappuzzo et al., 2018).